Show simple item record

2021-01-17Zeitschriftenartikel
SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi
dc.contributor.authorMeinus, C.
dc.contributor.authorSinger, R.
dc.contributor.authorNandi, B.
dc.contributor.authorJagot, O.
dc.contributor.authorBecker-Ziaja, B.
dc.contributor.authorKaro, B.
dc.contributor.authorMvula, B.
dc.contributor.authorJansen, A.
dc.contributor.authorBaumann, J.
dc.contributor.authorSchultz, A.
dc.date.accessioned2022-03-22T13:52:25Z
dc.date.available2022-03-22T13:52:25Z
dc.date.issued2021-01-17none
dc.identifier.other10.1016/j.ijid.2021.12.336
dc.identifier.urihttp://edoc.rki.de/176904/9534
dc.description.abstractBackground: COVID-19 transmission and disease dynamics in sub-Saharan Africa are not well understood. Our study aims to provide insight into COVID-19 epidemiology in Malawi by estimating SARS-CoV-2 prevalence and immunity after SARS-CoV-2 infection in a hospital-based setting. Methods: We conducted a hospital-based, convenience sampling, cross-sectional survey for SARS-CoV-2 in Lilongwe, Malawi. Participants answered a questionnaire and were tested for SARS-CoV-2 by enzyme-linked immunosorbent assay and real-time reverse-transcription polymerase chain reaction (RT-PCR). A surrogate virus neutralization test (sVNT) was performed in seropositive samples to estimate immunity. Poisson regression was used to assess SARS-CoV-2 point prevalence association with demographic and behavioral variables. Findings: The study included 930 participants. We found a combined point prevalence of 10.1%. Separately analyzed, RT-PCR positivity was 2.0%, and seropositivity was 9.3%. Of tested seropositive samples, 90.1% were sVNT positive. We found a high rate (45.7%) of asymptomatic SARS-CoV-2 infection. SARS-CoV-2 point prevalence was significantly associated with being a healthcare worker. Interpretation: Our study suggests that official data underestimate COVID-19 transmission. Using sVNTs to estimate immunity in Malawi is feasible and revealed considerable post-infection immunity in our cohort. Subclinical infection and transmission are probably a game-changer in surveillance, mitigation and vaccination strategies.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectserosurveyeng
dc.subjectCOVID-19eng
dc.subjectprevalenceeng
dc.subjectimmunityeng
dc.subjectMalawieng
dc.subjectAfricaeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleSARS-CoV-2 prevalence and immunity: a hospital-based study from Malawinone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/9534-9
dc.type.versionpublishedVersionnone
local.edoc.container-titleInternational Journal of Infectious Diseasesnone
local.edoc.container-issn0022-1899none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.sciencedirect.com/science/article/pii/S1201971221012340none
local.edoc.container-publisher-nameOxford University Pressnone
local.edoc.container-volume116none
local.edoc.container-year2021none
local.edoc.container-firstpage157none
local.edoc.container-lastpage165none
dc.description.versionPeer Reviewednone

Show simple item record